Get the Stockscreener App
0.6901
1.40%
-0.0098
After Hours:
.70
0.0099
+1.43%
Scynexis Inc stock is traded at $0.6901, with a volume of 291.28K.
It is down -1.40% in the last 24 hours and up +2.27% over the past month.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
See More
Previous Close:
$0.6999
Open:
$0.69
24h Volume:
291.28K
Relative Volume:
1.82
Market Cap:
$26.93M
Revenue:
$135.87M
Net Income/Loss:
$72.20M
P/E Ratio:
0.486
EPS:
1.42
Net Cash Flow:
$45.09M
1W Performance:
-6.49%
1M Performance:
+2.27%
6M Performance:
-35.50%
1Y Performance:
-67.60%
1-Day Range:
$0.675
$0.6901
1-Week Range:
$0.675
$0.7439
52-Week Range:
$0.66
$2.13
Scynexis Inc Stock (SCYX) Company Profile
Name
Scynexis Inc
Sector
Phone
201-884-5485
Address
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Compare SCYX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
0.6901 | 27.31M | 135.87M | 72.20M | 45.09M | 1.42 |
|
ZTS
Zoetis Inc
|
145.79 | 66.25B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 42.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.43 | 43.30B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.45 | 19.30B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
128.23 | 13.53B | 2.41B | 305.80M | 492.20M | 2.95 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-21 | Initiated | Guggenheim | Buy |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-18 | Upgrade | Needham | Hold → Buy |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-10-17 | Initiated | ROTH Capital | Buy |
| May-09-17 | Downgrade | Needham | Buy → Hold |
| Mar-03-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-20-16 | Initiated | H.C. Wainwright | Buy |
| Oct-07-16 | Upgrade | WBB Securities | Buy → Strong Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Aug-17-16 | Initiated | Guggenheim | Buy |
| Aug-09-16 | Reiterated | Needham | Buy |
| Aug-09-16 | Upgrade | WBB Securities | Speculative Buy → Buy |
| Mar-28-16 | Initiated | Brean Capital | Buy |
| Dec-29-15 | Initiated | WBB Securities | Speculative Buy |
| Nov-16-15 | Reiterated | RBC Capital Mkts | Outperform |
| Jun-10-15 | Initiated | Needham | Buy |
| May-29-14 | Initiated | Canaccord Genuity | Buy |
| May-29-14 | Initiated | RBC Capital Mkts | Outperform |
View All
Scynexis Inc Stock (SCYX) Latest News
When is SCYNEXIS Inc. stock expected to show significant growthDaily Trading Insights With High Returns - jammulinksnews.com
Technical analysis overview for SCYNEXIS Inc. stockFree Early Entry Tips With Low Risk Zone - Newser
Biotech Co. Beats Investor Suit Over Antifungal Drug Recall - Law360
Scynexis Beats Investor’s Suit Over Drug Recall Risk for Now - Bloomberg Law News
How did SCYX's Q1 2024 EPS surprise impact short-term trading? - AInvest
What are analysts’ price targets for SCYNEXIS Inc. in the next 12 monthsFinancial News Watchlist For 2025 - jammulinksnews.com
Why SCYNEXIS Inc. stock attracts strong analyst attentionStrategy Builder for Growth Focused Traders - Newser
What makes SCYNEXIS Inc. stock price move sharplyReal Time Alerts Based on AI Prediction Triggered - beatles.ru
Published on: 2025-07-29 23:02:31 - metal.it
Candidemia Market Analysis and Forecast Report 2025-2035 Featuring Pfizer, Cidara Therapeutics, Scynexis, Merck, Basilea Pharmaceutica, Lupin Pharmaceuticals, Astellas PharmaResearchAndMarkets.com - FinancialContent
SCYNEXIS Inc. Stock Support and Resistance Levels You Should KnowDaily Market Momentum Summary and Strategy - Newser
Volatility clustering patterns for SCYNEXIS Inc.Free Investment Playbook for Growing Markets - Newser
SCYNEXIS Inc. Earnings Report Breakdown: What Investors Should KnowWeekly Chart Analysis With Entry Advice Provided - metal.it
What are the latest earnings results for SCYNEXIS Inc.Achieve consistent profits with proven methods - jammulinksnews.com
How strong is SCYNEXIS Inc. company’s balance sheetInvest confidently with professional market insights - jammulinksnews.com
Does SCYNEXIS Inc. stock perform well during market downturnsMarket-crushing profits - jammulinksnews.com
Published on: 2025-07-28 05:37:03 - jammulinksnews.com
What catalysts could drive SCYNEXIS Inc. stock higher in 2025Achieve consistent profits with expert advice - jammulinksnews.com
Published on: 2025-07-28 03:42:51 - jammulinksnews.com
How volatile is SCYNEXIS Inc. stock compared to the marketAchieve triple-digit returns with smart investing - jammulinksnews.com
What are SCYNEXIS Inc. company’s key revenue driversRecord-breaking gains - jammulinksnews.com
SCYNEXIS Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingFree Stock Investment Discussion Area - Newser
What analysts say about SCYNEXIS Inc. stockFree Stock Market Trend Analysis - PrintWeekIndia
Is SCYNEXIS Inc. a good long term investmentTremendous growth opportunities - Autocar Professional
What drives SCYNEXIS Inc. stock priceFastest return on investment - Autocar Professional
SCYNEXIS Inc. Stock Analysis and ForecastFast-track wealth growth - Autocar Professional
Is ATH.PRA a good long term investmentSkyrocketing returns - Jammu Links News
Scynexis Inc Stock (SCYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):